NO985636L - aPL immunoreaktive peptider, konjugater derav og metoder for behandling av aPL antistoff-medierte patologier - Google Patents

aPL immunoreaktive peptider, konjugater derav og metoder for behandling av aPL antistoff-medierte patologier

Info

Publication number
NO985636L
NO985636L NO985636A NO985636A NO985636L NO 985636 L NO985636 L NO 985636L NO 985636 A NO985636 A NO 985636A NO 985636 A NO985636 A NO 985636A NO 985636 L NO985636 L NO 985636L
Authority
NO
Norway
Prior art keywords
apl
conjugates
methods
treating
antibody
Prior art date
Application number
NO985636A
Other languages
English (en)
Norwegian (no)
Other versions
NO985636D0 (no
Inventor
Edward Jess Victoria
David Matthew Marquis
David S Jones
Lin Yu
Original Assignee
Jolla Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/660,092 external-priority patent/US6207160B1/en
Application filed by Jolla Pharma filed Critical Jolla Pharma
Publication of NO985636D0 publication Critical patent/NO985636D0/no
Publication of NO985636L publication Critical patent/NO985636L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
NO985636A 1996-06-06 1998-12-03 aPL immunoreaktive peptider, konjugater derav og metoder for behandling av aPL antistoff-medierte patologier NO985636L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/660,092 US6207160B1 (en) 1995-06-07 1996-06-06 aPL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies
US76050896A 1996-12-05 1996-12-05
PCT/US1997/010075 WO1997046251A1 (en) 1996-06-06 1997-06-06 aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES

Publications (2)

Publication Number Publication Date
NO985636D0 NO985636D0 (no) 1998-12-03
NO985636L true NO985636L (no) 1999-02-08

Family

ID=27097975

Family Applications (1)

Application Number Title Priority Date Filing Date
NO985636A NO985636L (no) 1996-06-06 1998-12-03 aPL immunoreaktive peptider, konjugater derav og metoder for behandling av aPL antistoff-medierte patologier

Country Status (7)

Country Link
EP (1) EP0954531A1 (ja)
JP (1) JP2000512981A (ja)
KR (1) KR20000016414A (ja)
AU (1) AU734638B2 (ja)
CA (1) CA2256449A1 (ja)
NO (1) NO985636L (ja)
WO (1) WO1997046251A1 (ja)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2113940T3 (es) * 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US5874409A (en) 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US6858210B1 (en) * 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
WO2000006717A2 (en) 1998-07-27 2000-02-10 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein
US6238860B1 (en) 1998-11-05 2001-05-29 Dyax Corp. Binding moieties for human parvovirus B19
US6458953B1 (en) 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
US6399578B1 (en) 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
US6197526B1 (en) 1999-01-04 2001-03-06 Dyax Corp. Polypeptides for binding human factor VIII and fragments of human factor VIII
US7112438B2 (en) 1999-01-04 2006-09-26 Dyax Corp. Binding molecules for human factor VIII and factor VIII-like proteins
GB9919452D0 (en) * 1999-08-17 1999-10-20 Osteometer Biotech As Specific autoimmune reactions against isomerised/optically inverted epitopes:application for diagnosis of autoimmune diseases
AU7646100A (en) * 1999-11-05 2001-05-14 Novozymes A/S A high throughput screening (hts) method
KR20020059808A (ko) 1999-11-28 2002-07-13 와이즈먼 앤드루 항체 친화도에 기초한 루프스 치료방법 및 그것의 사용을위한 스크리닝 방법과 조성물
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
PT2281843T (pt) 2000-06-16 2017-01-02 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
EP2267018A3 (en) 2000-08-18 2011-04-20 Human Genome Sciences, Inc. Binding polypeptides for B lymphocyte stimulator protein (BLyS)
US20030091565A1 (en) 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
AU2002250032B2 (en) 2001-02-09 2008-06-05 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
EP2228389B1 (en) 2001-04-13 2015-07-08 Human Genome Sciences, Inc. Antibodies against vascular endothelial growth factor 2
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
KR100607612B1 (ko) 2001-06-20 2006-08-02 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
EP2423335B1 (en) 2001-06-21 2014-05-14 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same
EP2153843B1 (en) 2001-09-18 2012-08-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20030228305A1 (en) 2002-01-02 2003-12-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1571968A4 (en) 2002-04-16 2007-10-17 Genentech Inc COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TUMORS
KR20050052467A (ko) 2002-08-12 2005-06-02 다이나박스 테크놀로지 코퍼레이션 면역조절 조성물, 이의 제조방법 및 이의 이용방법
PL2784084T3 (pl) 2003-07-08 2020-03-31 Genentech, Inc. Przeciwciała antagonistyczne wobec heterologicznych polipeptydów IL-17A/F
SI2161283T1 (sl) 2003-11-17 2014-10-30 Genentech, Inc. Sestavki, ki obsegajo protitelesa proti CD79b, konjugirana na sredstvo, ki inhibira rast, ali na citotoksično sredstvo, in postopki za zdravljenje tumorja hematopoetskega izvora
NZ553581A (en) 2004-09-01 2011-04-29 Dynavax Tech Corp Methods and compositions for inhibition of innate immune responses and autoimmunity using immunoregulatory polynucleotides with a TGC sequence
EP2050763A3 (en) 2005-03-10 2009-07-15 Genentech, Inc. Methods and compositions for modulating vascular integrity
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
EP2614839A3 (en) 2006-04-05 2015-01-28 Genentech, Inc. Method for using BOC/CDO to modulate hedgehog signaling
CA2660286A1 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
EP2354254A1 (en) 2006-09-06 2011-08-10 Ortho-McNeil Pharmaceutical, Inc. Biomarkers for assessing response to C-met treatment
EP2083017A4 (en) 2006-09-14 2011-01-12 Med & Biological Lab Co Ltd ANTIBODIES HAVING INCREASED ADCC ACTIVITY AND METHOD FOR PRODUCING THE SAME
WO2008103962A2 (en) 2007-02-22 2008-08-28 Genentech, Inc. Methods for detecting inflammatory bowel disease
JP5749492B2 (ja) 2007-10-26 2015-07-15 ダイナバックス テクノロジーズ コーポレイション 免疫応答と自己免疫を阻害する方法及び組成物
WO2009148896A2 (en) 2008-05-29 2009-12-10 Nuclea Biotechnologies, LLC Anti-phospho-akt antibodies
CN102124030B (zh) 2008-06-20 2015-06-17 国立大学法人冈山大学 抗氧化LDL/β2GPI复合物的抗体及其用途
US9182406B2 (en) 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
CN102711826B (zh) 2009-10-22 2017-03-29 霍夫曼-拉罗奇有限公司 用于调控巨噬细胞刺激性蛋白的hepsin活化的方法和组合物
PE20121584A1 (es) 2009-11-30 2012-11-29 Genentech Inc Composiciones y metodos para el diagnostico y el tratamiento de tumores
AR080243A1 (es) 2010-02-23 2012-03-21 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores
MA34291B1 (fr) 2010-05-03 2013-06-01 Genentech Inc Compositions et méthodes de diagnostic et de traitement d'une tumeur
BR112012032240A2 (pt) 2010-06-16 2019-09-24 Dynavax Technologies Corporation método de tratamento utilizando inibidores tlr7 e/ou tlr9
AU2011348220B2 (en) * 2010-12-22 2017-09-07 The Salk Institute For Biological Studies Cyclic CRF antagonist peptides
US9428789B2 (en) 2011-03-21 2016-08-30 Biodesy, Inc. Classification of kinase inhibitors using nonlinear optical techniques
MX2014003094A (es) 2011-09-15 2014-04-25 Genentech Inc Metodos para promover diferenciacion.
EP2766000A2 (en) 2011-10-15 2014-08-20 F.Hoffmann-La Roche Ag Scd1 antagonists for treating cancer
EP2804630B1 (en) 2012-01-18 2017-10-18 F. Hoffmann-La Roche AG Methods of using fgf19 modulators
KR102148303B1 (ko) 2012-02-11 2020-08-26 제넨테크, 인크. R-스폰딘 전위 및 그의 사용 방법
KR20140135198A (ko) 2012-03-16 2014-11-25 에프. 호프만-라 로슈 아게 Pak1 억제제로 흑색종을 치료하는 방법
US9139863B2 (en) 2012-03-16 2015-09-22 Genentech, Inc. Engineered conformationally-stabilized proteins
MX2014010943A (es) 2012-03-16 2014-11-26 Genentech Inc Proteinas estabilizadas conformacionalmente de ingenieria.
JP6302460B2 (ja) 2012-04-25 2018-03-28 バイオデシー， インコーポレイテッド タンパク質のアロステリックモジュレーターを検出するための方法
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
US9228184B2 (en) 2012-09-29 2016-01-05 Dynavax Technologies Corporation Human toll-like receptor inhibitors and methods of use thereof
CN110079599B (zh) 2013-03-15 2024-06-04 豪夫迈·罗氏有限公司 治疗pd-1和pd-l1相关疾患的生物标志物和方法
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
EP3146071B1 (en) 2014-05-23 2020-09-02 F. Hoffmann-La Roche AG Mit biomarkers and methods using the same
WO2015196070A1 (en) 2014-06-20 2015-12-23 Genentech, Inc. Chagasin-based scaffold compositions, methods, and uses
EP3237906B8 (en) 2014-12-23 2020-10-28 Bluelight Therapeutics, Inc. Attachment of proteins to interfaces for use in nonlinear optical detection
CN110198729A (zh) 2016-09-09 2019-09-03 豪夫迈·罗氏有限公司 卷曲蛋白的选择性肽抑制剂
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
EP3615569A1 (en) 2017-04-25 2020-03-04 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
WO2019018629A1 (en) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
EP3966244A1 (en) 2019-05-09 2022-03-16 F. Hoffmann-La Roche AG Methods of making antibodies
CN112480209B (zh) * 2020-11-16 2022-03-04 昆明学院 一种抗皮肤光损伤保护活性多肽rl-pl9及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2044142A1 (en) * 1989-10-19 1991-04-20 Eiji Matsuura Carrier for binding of anti-phospholipid antibodies, an immunoassay method using the same and a kit therefor
US5552391A (en) * 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5268454A (en) * 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
WO1991015772A1 (en) * 1990-04-06 1991-10-17 Yamasa Shoyu Co. Ltd. Methods for determining phospholipids and antibodies thereof
EP0523035B1 (de) * 1990-04-10 1994-10-12 Masur, Walter Verfahren zum betreiben einer kompressionswärmepumpe, sowie kompressionswärmepumpe
DE69334133T2 (de) * 1993-09-08 2007-12-27 La Jolla Pharmaceutical Co., San Diego Chemisch definierten nicht-polymer wertigen Plattformmolokülen und ihren Konjugaten
US5874409A (en) * 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies

Also Published As

Publication number Publication date
WO1997046251A1 (en) 1997-12-11
KR20000016414A (ko) 2000-03-25
AU3640497A (en) 1998-01-05
EP0954531A1 (en) 1999-11-10
NO985636D0 (no) 1998-12-03
CA2256449A1 (en) 1997-12-11
AU734638B2 (en) 2001-06-21
EP0954531A4 (en) 1999-08-31
JP2000512981A (ja) 2000-10-03

Similar Documents

Publication Publication Date Title
NO985636D0 (no) aPL immunoreaktive peptider, konjugater derav og metoder for behandling av aPL antistoff-medierte patologier
EP0833648A4 (en) PLA IMMUNE REACTION PEPTIDES, CONJUGATES THEREOF, AND METHODS OF TREATING DISEASES INDUCED BY PLA ANTIBODIES
DE69730043D1 (de) Implantierbare eletrodenleitung
HUP0003401A3 (en) Improved methods for processing activated protein c
ZA9811593B (en) Substantially pure histidine-linked protein polymer conjugates
ZA986072B (en) Adsorption apparatus and methods.
DE69718990D1 (de) Behandlungsgerät
ZA97631B (en) Migraine treatment.
IL118969A0 (en) Purse string suture apparatus
EP0911397A4 (en) TUMORANTANT PROTEINS, THEIR GENES, AND TUMORANTANT PEPTIDES
EP0904539A4 (en) INHIBITION OF PROTEIN INTERACTION
GB2311840B (en) UV dryer with improved reflector
GB9606126D0 (en) Biosensors
ZA973211B (en) Support post.
IL117674A (en) Uv reflector
GB2318340B (en) Envelope closing apparatus
ZA968185B (en) Protein.
ZA989574B (en) Indole derivative useful in therapy.
TR199600586A3 (tr) Ürün ve hizmetlerin karsiliginin ödenmesi için proses.
KR970052847U (ko) 시트 제품 적재 장치
EP0915100A4 (en) NEW PROTEIN
GB9607130D0 (en) Uv dryers
ZA968224B (en) Hair-styling apparatus.
BR9705072A (pt) Aparelho de difusão
AU787P (en) APRIL GLO Prunus persica var. nucipersica

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application